• Keine Ergebnisse gefunden

AEBERSOLD, P., C. HYATT, S. JOHNSON, K. HINES, L. KORCAK, M. SANDERS, M.

LOTZE, S. TOPALIAN, J. YANG, und S. A. ROSENBERG (1991):

Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with cli-nical response.

J. Natl. Cancer Inst. 83: 932-937.

ALEXANDER-MILLER, M. A., G. R. LEGGATT, und J. A. BERZOFSKY (1996):

Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adopti-ve immunotherapy.

Proc. Natl. Acad. Sci. U. S. A 93: 4102-4107.

ALTMAN, J. D., P. A. MOSS, P. J. GOULDER, D. H. BAROUCH, M. G. MCHEYZER-WILLIAMS, J. I. BELL, A. J. MCMICHAEL, und M. M. DAVIS (1996):

Phenotypic analysis of antigen-specific T lymphocytes.

Science 274: 94-96.

APPLEMAN, L. J., und V. A. BOUSSIOTIS (2003):

T cell anergy and costimulation.

Immunol. Rev. 192: 161-180.

ASHLEY, D. M., B. FAIOLA, S. NAIR, L. P. HALE, D. D. BIGNER, und E. GILBOA (1997):

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.

J. Exp. Med. 186: 1177-1182.

BANCHEREAU, J., und R. M. STEINMAN (1998):

Dendritic cells and the control of immunity.

Nature 392: 245-252.

BANCHEREAU, J., und A. K. PALUCKA (2005):

Dendritic cells as therapeutic vaccines against cancer.

Nat. Rev. Immunol. 5: 296-306.

BARKER, C. F., und R. E. BILLINGHAM (1977):

Immunologically privileged sites.

Adv. Immunol. 25: 1-54.

BECKER, F. F., D. STILLMAN, und S. SELL (1977):

Serum alpha-fetoprotein in a mouse strain (C3H-Avy fB) with spontaneous hepatocellular carcinomas.

Cancer Res. 37: 870-872.

BEDNAREK, M. A., S. Y. SAUMA, M. C. GAMMON, G. PORTER, S. TAMHANKAR, A. R.

WILLIAMSON, und H. J. ZWEERINK (1991):

The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellu-lar loading of HLA-A2.

J. Immunol. 147: 4047-4053.

BERGWELT-BAILDON, M. S., R. H. VONDERHEIDE, B. MAECKER, N. HIRANO, K. S.

ANDERSON, M. O. BUTLER, Z. XIA, W. Y. ZENG, K. W. WUCHERPFENNIG, L. M.

NADLER, und J. L. SCHULTZE (2002):

Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical applica-tion.

Blood 99: 3319-3325.

BOON, T., A. VAN PEL, E. DE PLAEN, P. CHOMEZ, C. LURQUIN, J. P. SZIKORA, C.

SIBILLE, B. MARIAME, E. B. VAN DEN, B. LETHE, und . (1989):

Genes coding for T-cell-defined tum transplantation antigens: point mutations, antigenic peptides, and subgenic expression.

Cold Spring Harb. Symp. Quant. Biol. 54 Pt 1: 587-596.

BOON, T., T. F. GAJEWSKI, und P. G. COULIE (1995):

From defined human tumor antigens to effective immunization?

Immunol. Today 16: 334-336.

BOON, A. C., E. FRINGUELLI, Y. M. GRAUS, R. A. FOUCHIER, K. SINTNICOLAAS, A.

M. IORIO, G. F. RIMMELZWAAN, und A. D. OSTERHAUS (2002):

Influenza A virus specific T cell immunity in humans during aging.

Virology 299: 100-108.

BOON, A. C., G. DE MUTSERT, R. A. FOUCHIER, K. SINTNICOLAAS, A. D. OSTER-HAUS, und G. F. RIMMELZWAAN (2004):

Preferential HLA usage in the influenza virus-specific CTL response.

J. Immunol. 172: 4435-4443.

BOSMA, G. C., R. P. CUSTER, und M. J. BOSMA (1983):

A severe combined immunodeficiency mutation in the mouse.

Nature 301: 527-530.

BOUVIER, M. (2003):

Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective.

Mol. Immunol. 39: 697-706.

BRENTJENS, R. J., J. B. LATOUCHE, E. SANTOS, F. MARTI, M. C. GONG, C. LYDDA-NE, P. D. KING, S. LARSON, M. WEISS, I. RIVIERE, und M. SADELAIN (2003):

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Nat. Med. 9: 279-286.

BRETSCHER, P., und M. COHN (1970):

A theory of self-nonself discrimination.

Science 169: 1042-1049.

BRODIE, S. J., B. K. PATTERSON, D. A. LEWINSOHN, K. DIEM, D. SPACH, P. D.

GREENBERG, S. R. RIDDELL, und L. COREY (2000):

HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV rep-lication and cell death.

J. Clin. Invest 105: 1407-1417.

BROWN, J. H., T. S. JARDETZKY, J. C. GORGA, L. J. STERN, R. G. URBAN, J. L.

STROMINGER, und D. C. WILEY (1993):

Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.

Nature 364: 33-39.

BRUNNER, K. T., J. MAUEL, J. C. CEROTTINI, und B. CHAPUIS (1968):

Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled alloge-neic target cells in vitro; inhibition by isoantibody and by drugs.

Immunology 14: 181-196.

BRYANT, P., und H. PLOEGH (2004):

Class II MHC peptide loading by the professionals.

Curr. Opin. Immunol. 16: 96-102.

BURNET, F. M. (1970):

The concept of immunological surveillance.

Prog. Exp. Tumor Res. 13: 1-27.

BUTTERFIELD, L. H., A. KOH, W. MENG, C. M. VOLLMER, A. RIBAS, V. DISSETTE, E.

LEE, J. A. GLASPY, W. H. MCBRIDE, und J. S. ECONOMOU (1999):

Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.

Cancer Res. 59: 3134-3142.

BUTTERFIELD, L. H., W. S. MENG, A. KOH, C. M. VOLLMER, A. RIBAS, V. B. DISSET-TE, K. FAULL, J. A. GLASPY, W. H. MCBRIDE, und J. S. ECONOMOU (2001):

T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.

J. Immunol. 166: 5300-5308.

BUTTERFIELD, L. H., A. RIBAS, W. S. MENG, V. B. DISSETTE, S. AMARNANI, H. T.

VU, E. SEJA, K. TODD, J. A. GLASPY, W. H. MCBRIDE, und J. S. ECONOMOU (2003):

T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

Clin. Cancer Res. 9: 5902-5908.

BUTTERFIELD, L. H. (2004):

Immunotherapeutic strategies for hepatocellular carcinoma.

Gastroenterology 127: S232-S241.

CELLA, M., F. SALLUSTO, und A. LANZAVECCHIA (1997):

Origin, maturation and antigen presenting function of dendritic cells.

Curr. Opin. Immunol. 9: 10-16.

CHAPUT, N., J. TAIEB, F. ANDRE, und L. ZITVOGEL (2005):

The potential of exosomes in immunotherapy.

Expert. Opin. Biol. Ther. 5: 737-747.

CHEN, L., S. ASHE, W. A. BRADY, I. HELLSTROM, K. E. HELLSTROM, J. A. LEDBET-TER, P. MCGOWAN, und P. S. LINSLEY (1992):

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte mole-cules CD28 and CTLA-4.

Cell 71: 1093-1102.

CHEN, H., J. O. EGAN, und J. F. CHIU (1997a):

Regulation and activities of alpha-fetoprotein.

Crit Rev. Eukaryot. Gene Expr. 7: 11-41.

CHEN, Y. T., M. J. SCANLAN, U. SAHIN, O. TURECI, A. O. GURE, S. TSANG, B. WILLI-AMSON, E. STOCKERT, M. PFREUNDSCHUH, und L. J. OLD (1997b):

A testicular antigen aberrantly expressed in human cancers detected by autologous anti-body screening.

Proc. Natl. Acad. Sci. U. S. A 94: 1914-1918.

CHEN, C. H., G. J. CHEN, H. S. LEE, G. T. HUANG, P. M. YANG, L. J. TSAI, D. S.

CHEN, und J. C. SHEU (2001):

Expressions of cancer-testis antigens in human hepatocellular carcinomas.

Cancer Lett. 164: 189-195.

CHICZ, R. M., R. G. URBAN, W. S. LANE, J. C. GORGA, L. J. STERN, D. A. VIGNALI, und J. L. STROMINGER (1992):

Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.

Nature 358: 764-768.

COLEY, W. B. (1893):

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases.

Clin. Orthop. Relat Res. 3-11.

COMANS-BITTER, W. M., R. DE GROOT, B. R. VAN DEN, H. J. NEIJENS, W. C. HOP, K. GROENEVELD, H. HOOIJKAAS, und J. J. VAN DONGEN (1997):

Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations.

J. Pediatr. 130: 388-393.

COX, A. L., J. SKIPPER, Y. CHEN, R. A. HENDERSON, T. L. DARROW, J. SHABANO-WITZ, V. H. ENGELHARD, D. F. HUNT, und C. L. SLINGLUFF, Jr. (1994):

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

Science 264: 716-719.

CROWLEY, N. J., C. E. VERVAERT, und H. F. SEIGLER (1992):

Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells.

Cancer Res. 52: 394-399.

CURTSINGER, J. M., C. S. SCHMIDT, A. MONDINO, D. C. LINS, R. M. KEDL, M. K.

JENKINS, und M. F. MESCHER (1999):

Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells.

J. Immunol. 162: 3256-3262.

DARNELL, R. B., und J. B. POSNER (2003):

Observing the invisible: successful tumor immunity in humans.

Nat. Immunol. 4: 201-

DE PLAEN, E., K. ARDEN, C. TRAVERSARI, J. J. GAFORIO, J. P. SZIKORA, C. DE SMET, F. BRASSEUR, B. P. VAN DER, B. LETHE, C. LURQUIN, und . (1994):

Structure, chromosomal localization, and expression of 12 genes of the MAGE family.

Immunogenetics 40: 360-369.

DE SMET, C., O. DE BACKER, I. FARAONI, C. LURQUIN, F. BRASSEUR, und T. BOON (1996):

The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide de-methylation.

Proc. Natl. Acad. Sci. U. S. A 93: 7149-7153.

DE VISSER, K. E., T. N. SCHUMACHER, und A. M. KRUISBEEK (2003):

CD8+ T cell tolerance and cancer immunotherapy.

J. Immunother. 26: 1-11.

DEL MAZO, J., G. PRANTERA, M. TORRES, und M. FERRARO (1994):

DNA methylation changes during mouse spermatogenesis.

Chromosome. Res. 2: 147-152.

DENKBERG, G., C. J. COHEN, D. SEGAL, A. F. KIRKIN, und Y. REITER (2000):

Recombinant human single-chain MHC-peptide complexes made from E. coli By in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor asso-ciated antigens.

Eur. J. Immunol. 30: 3522-3532.

DRAKE, C. G., E. JAFFEE, und D. M. PARDOLL (2006):

Mechanisms of immune evasion by tumors.

Adv. Immunol. 90: 51-81.

DRANOFF, G., E. JAFFEE, A. LAZENBY, P. GOLUMBEK, H. LEVITSKY, K. BROSE, V.

JACKSON, H. HAMADA, D. PARDOLL, und R. C. MULLIGAN (1993):

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Proc. Natl. Acad. Sci. U. S. A 90: 3539-3543.

DUDLEY, M. E., J. R. WUNDERLICH, P. F. ROBBINS, J. C. YANG, P. HWU, D. J.

SCHWARTZENTRUBER, S. L. TOPALIAN, R. SHERRY, N. P. RESTIFO, A. M. HUBICKI, M. R. ROBINSON, M. RAFFELD, P. DURAY, C. A. SEIPP, L. ROGERS-FREEZER, K. E.

MORTON, S. A. MAVROUKAKIS, D. E. WHITE, und S. A. ROSENBERG (2002):

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Science 298: 850-854.

DUDLEY, M. E., und S. A. ROSENBERG (2003):

Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Nat. Rev. Cancer 3: 666-675.

DUNBAR, P. R., G. S. OGG, J. CHEN, N. RUST, B. P. VAN DER, und V. CERUNDOLO (1998):

Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood.

Curr. Biol. 8: 413-416.

DUNN, G. P., A. T. BRUCE, H. IKEDA, L. J. OLD, und R. D. SCHREIBER (2002):

Cancer immunoediting: from immunosurveillance to tumor escape.

Nat. Immunol. 3: 991-998.

DUNN, G. P., L. J. OLD, und R. D. SCHREIBER (2004):

The three Es of cancer immunoediting.

Annu. Rev. Immunol. 22: 329-360.

ENGVALL, E., und P. PERLMAN (1971):

Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Immunochemistry. 8: 871-874.

ESPINOSA, E., J. TABIASCO, D. HUDRISIER, und J. J. FOURNIE (2002):

Synaptic transfer by human gamma delta T cells stimulated with soluble or cellular anti-gens.

J. Immunol. 168: 6336-6343.

ESSEX, M., C. K. GRANT, S. M. COTTER, A. H. SLISKI, und W. D. HARDY, Jr. (1979):

Leukemia specific antigens: FOCMA and immune surveillance.

Haematol. Blood Transfus. 23: 453-486.

FALK, K., O. ROTZSCHKE, S. STEVANOVIC, G. JUNG, und H. G. RAMMENSEE (1991):

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Nature 351: 290-296.

FEUERER, M., P. BECKHOVE, L. BAI, E. F. SOLOMAYER, G. BASTERT, I. J. DIEL, C.

PEDAIN, M. OBERNIEDERMAYR, V. SCHIRRMACHER, und V. UMANSKY (2001):

Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow.

Nat. Med. 7: 452-458.

FINN, O. J., K. R. JEROME, R. A. HENDERSON, G. PECHER, N. DOMENECH, J. MA-GARIAN-BLANDER, und S. M. BARRATT-BOYES (1995):

MUC-1 epithelial tumor mucin-based immunity and cancer vaccines.

Immunol. Rev. 145: 61-89.

FISCH, P., M. MALKOVSKY, S. KOVATS, E. STURM, E. BRAAKMAN, B. S. KLEIN, S. D.

VOSS, L. W. MORRISSEY, R. DEMARS, W. J. WELCH, und . (1990):

Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells.

Science 250: 1269-1273.

GABRILOVICH, D. (2004):

Mechanisms and functional significance of tumour-induced dendritic-cell defects.

Nat. Rev. Immunol. 4: 941-952.

GACZYNSKA, M., K. L. ROCK, und A. L. GOLDBERG (1993):

Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by protea-somes.

Nature 365: 264-267.

GAGLIARDI, M. C., G. DE PETRILLO, S. SALEMI, L. BOFFA, M. G. LONGOBARDI, P.

DELLABONA, G. CASORATI, N. TANIGAKI, R. HARRIS, A. LANZAVECCHIA, und . (1995):

Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro.

Int. Immunol. 7: 1741-1752.

GAMREKELASHVILI, J., C. KRUGER, R. VON WASIELEWSKI, M. HOFFMANN, K. M.

HUSTER, D. H. BUSCH, M. P. MANNS, F. KORANGY, und T. F. GRETEN (2007):

Necrotic tumor cell death in vivo impairs tumor-specific immune responses.

J. Immunol. 178: 1573-1580.

GARBOCZI, D. N., D. T. HUNG, und D. C. WILEY (1992):

HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Esche-richia coli and complexed with single antigenic peptides.

Proc. Natl. Acad. Sci. U. S. A 89: 3429-3433.

GARLIE, N. K., A. V. LEFEVER, R. E. SIEBENLIST, B. L. LEVINE, C. H. JUNE, und L. G.

LUM (1999):

T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer.

J. Immunother. 22: 336-345.

GATTINONI, L., C. A. KLEBANOFF, D. C. PALMER, C. WRZESINSKI, K. KERSTANN, Z.

YU, S. E. FINKELSTEIN, M. R. THEORET, S. A. ROSENBERG, und N. P. RESTIFO (2005):

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor effica-cy of adoptively transferred CD8+ T cells.

J. Clin. Invest 115: 1616-1626.

GATTINONI, L., D. J. POWELL, Jr., S. A. ROSENBERG, und N. P. RESTIFO (2006):

Adoptive immunotherapy for cancer: building on success.

Nat. Rev. Immunol. 6: 383-393.

GILEADI, U., H. T. MOINS-TEISSERENC, I. CORREA, B. L. BOOTH, Jr., P. R. DUNBAR, A. K. SEWELL, J. TROWSDALE, R. E. PHILLIPS, und V. CERUNDOLO (1999):

Generation of an immunodominant CTL epitope is affected by proteasome subunit compo-sition and stability of the antigenic protein.

J. Immunol. 163: 6045-6052.

GIRLING, A., J. BARTKOVA, J. BURCHELL, S. GENDLER, C. GILLETT, und J. TAYLOR-PAPADIMITRIOU (1989):

A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal an-tibody SM-3 is selectively exposed in a range of primary carcinomas.

Int. J. Cancer 43: 1072-1076.

GOLD, P., und S. O. FREEDMAN (1965):

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCI-NOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

J. Exp. Med. 121: 439-462.

GOLDSTEIN, S. A., und M. F. MESCHER (1986):

Cell-sized, supported artificial membranes (pseudocytes): response of precursor cytotoxic T lymphocytes to class I MHC proteins.

J. Immunol. 137: 3383-3392.

GONG, J., D. CHEN, M. KASHIWABA, und D. KUFE (1997):

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells.

Nat. Med. 3: 558-561.

GOTCH, F., J. ROTHBARD, K. HOWLAND, A. TOWNSEND, und A. MCMICHAEL (1987):

Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in associa-tion with HLA-A2.

Nature 326: 881-882.

GOTTSCHALK, S., O. L. EDWARDS, U. SILI, M. H. HULS, T. GOLTSOVA, A. R. DAVIS, H. E. HESLOP, und C. M. ROONEY (2003):

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adopti-ve immunotherapy of EBV-associated malignancies.

Blood 101: 1905-1912.

GREENBLATT, M. S., W. P. BENNETT, M. HOLLSTEIN, und C. C. HARRIS (1994):

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pa-thogenesis.

Cancer Res. 54: 4855-4878.

GRETEN, T. F., und E. M. JAFFEE (1999):

Cancer vaccines.

J. Clin. Oncol. 17: 1047-1060.

GRETEN, T. F., F. KORANGY, G. NEUMANN, H. WEDEMEYER, K. SCHLOTE, A. HEL-LER, S. SCHEFFER, D. M. PARDOLL, A. I. GARBE, J. P. SCHNECK, und M. P. MANNS (2002):

Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes.

J. Immunol. Methods 271: 125-135.

GROLL, M., L. DITZEL, J. LOWE, D. STOCK, M. BOCHTLER, H. D. BARTUNIK, und R.

HUBER (1997):

Structure of 20S proteasome from yeast at 2.4 A resolution.

Nature 386: 463-471.

HANSEN, T. H., und D. R. LEE (1997):

Mechanism of class I assembly with beta 2 microglobulin and loading with peptide.

Adv. Immunol. 64: 105-137.

HAQUE, T., P. L. AMLOT, N. HELLING, J. A. THOMAS, P. SWENY, K. ROLLES, A. K.

BURROUGHS, H. G. PRENTICE, und D. H. CRAWFORD (1998):

Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients.

J. Immunol. 160: 6204-6209.

HAQUE, T., G. M. WILKIE, C. TAYLOR, P. L. AMLOT, P. MURAD, A. ILEY, D. DOMBA-GODA, K. M. BRITTON, A. J. SWERDLOW, und D. H. CRAWFORD (2002):

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.

Lancet 360: 436-442.

HESLOP, H. E., M. K. BRENNER, und C. M. ROONEY (1994):

Donor T cells to treat EBV-associated lymphoma.

N. Engl. J. Med. 331: 679-680.

HILL, F. W., W. R. KLEIN, M. J. HOYER, V. P. RUTTEN, N. KOCK, J. W. KOTEN, P. A.

STEERENBERG, E. J. RUITENBERG, und W. DEN OTTER (1994a):

Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma.

Vet. Immunol. Immunopathol. 41: 19-29.

HILL, F. W., V. P. RUTTEN, M. H. HOYER, W. R. KLEIN, J. W. KOTEN, P. A. STEEREN-BERG, E. J. RUITENSTEEREN-BERG, und W. DEN OTTER (1994b):

Local bacillus Calmette-Guerin therapy for bovine vulval papilloma and carcinoma.

Cancer Immunol. Immunother. 39: 49-52.

HO, W. Y., J. N. BLATTMAN, M. L. DOSSETT, C. YEE, und P. D. GREENBERG (2003):

Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.

Cancer Cell 3: 431-437.

HOOGENDOORN, M., J. O. WOLBERS, W. M. SMIT, M. R. SCHAAFSMA, R. M. BARGE, R. WILLEMZE, und J. H. FALKENBURG (2004):

Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.

Leukemia 18: 1278-1287.

HOOGENDOORN, M., W. J. OLDE, W. M. SMIT, M. R. SCHAAFSMA, I. JEDEMA, R. M.

BARGE, R. WILLEMZE, und J. H. FALKENBURG (2005):

Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.

Clin. Cancer Res. 11: 5310-5318.

HUANG, Y., und R. L. WANGE (2004):

T cell receptor signaling: beyond complex complexes.

J. Biol. Chem. 279: 28827-28830.

HUNG, K., R. HAYASHI, A. LAFOND-WALKER, C. LOWENSTEIN, D. PARDOLL, und H.

LEVITSKY (1998):

The central role of CD4(+) T cells in the antitumor immune response.

J. Exp. Med. 188: 2357-2368.

HWANG, I., X. SHEN, und J. SPRENT (2003):

Direct stimulation of naive T cells by membrane vesicles from antigen-presenting cells:

distinct roles for CD54 and B7 molecules.

Proc. Natl. Acad. Sci. U. S. A 100: 6670-6675.

JAFFEE, E. M., R. H. HRUBAN, B. BIEDRZYCKI, D. LAHERU, K. SCHEPERS, P. R.

SAUTER, M. GOEMANN, J. COLEMAN, L. GROCHOW, R. C. DONEHOWER, K. D. LIL-LEMOE, S. O'REILLY, R. A. ABRAMS, D. M. PARDOLL, J. L. CAMERON, und C. J. YEO (2001):

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vacci-ne for pancreatic cancer: a phase I trial of safety and immuvacci-ne activation.

J. Clin. Oncol. 19: 145-156.

JAGER, E., Y. T. CHEN, J. W. DRIJFHOUT, J. KARBACH, M. RINGHOFFER, D. JAGER, M. ARAND, H. WADA, Y. NOGUCHI, E. STOCKERT, L. J. OLD, und A. KNUTH (1998):

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

J. Exp. Med. 187: 265-270.

JUNG, T., U. SCHAUER, C. HEUSSER, C. NEUMANN, und C. RIEGER (1993):

Detection of intracellular cytokines by flow cytometry.

J. Immunol. Methods 159: 197-207.

KARBACH, J., C. PAULIGK, A. BENDER, S. GNJATIC, K. FRANZMANN, C. WAHLE, D.

JAGER, A. KNUTH, L. J. OLD, und E. JAGER (2006):

Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.

Int. J. Cancer 118: 668-674.

KASS, R., J. AGHA, S. BELLONE, M. PALMIERI, S. CANE, E. BIGNOTTI, R. HENRY-TILLMAN, L. HUTCHINS, M. J. CANNON, S. KLIMBERG, und A. D. SANTIN (2003):

In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells.

J. Surg. Res. 112: 189-197.

KAUR, I., S. D. VOSS, R. S. GUPTA, K. SCHELL, P. FISCH, und P. M. SONDEL (1993):

Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells.

J. Immunol. 150: 2046-2055.

KERSHAW, M. H., M. W. TENG, M. J. SMYTH, und P. K. DARCY (2005):

Supernatural T cells: genetic modification of T cells for cancer therapy.

Nat. Rev. Immunol. 5: 928-940.

KHANNA, R., S. BELL, M. SHERRITT, A. GALBRAITH, S. R. BURROWS, L. RAFTER, B.

CLARKE, R. SLAUGHTER, M. C. FALK, J. DOUGLASS, T. WILLIAMS, S. L. ELLIOTT, und D. J. MOSS (1999):

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid or-gan transplant patients with posttransplant lymphoproliferative disease.

Proc. Natl. Acad. Sci. U. S. A 96: 10391-10396.

KHANNA, R., J. TELLAM, J. DURAISWAMY, und L. COOPER (2001):

Immunotherapeutic strategies for EBV-associated malignancies.

Trends Mol. Med. 7: 270-276.

KIM, J. V., J. B. LATOUCHE, I. RIVIERE, und M. SADELAIN (2004):

The ABCs of artificial antigen presentation.

Nat. Biotechnol. 22: 403-410.

KINNUNEN, R.E., T. TALLBERG, H. STENBACK u. S. SARNA (1999):

Equine sarcoid tumour treated by autogenous tumour vaccine Anticancer Res 19, 3367-3374

KIRCHER, M. F., J. R. ALLPORT, E. E. GRAVES, V. LOVE, L. JOSEPHSON, A. H.

LICHTMAN, und R. WEISSLEDER (2003):

In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors.

Cancer Res. 63: 6838-6846.

KIRKWOOD, J. M., M.T. LOTZE und J.M. YASKO (1994):

Current cancer therapeutics

Current Medicine Philadelphia p. 344

KITAO, S., T. YAMADA, T. ISHIKAWA, H. MADARAME, M. FURUICHI, S. NEO, R. TSU-CHIYA, und K. KOBAYASHI (2006):

Alpha-fetoprotein in serum and tumor tissues in dogs with hepatocellular carcinoma.

J. Vet. Diagn. Invest 18: 291-295.

KLEBANOFF, C. A., L. GATTINONI, P. TORABI-PARIZI, K. KERSTANN, A. R. CARDO-NES, S. E. FINKELSTEIN, D. C. PALMER, P. A. ANTONY, S. T. HWANG, S. A. ROSEN-BERG, T. A. WALDMANN, und N. P. RESTIFO (2005a):

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity com-pared with effector memory T cells.

Proc. Natl. Acad. Sci. U. S. A 102: 9571-9576.

KLEBANOFF, C. A., H. T. KHONG, P. A. ANTONY, D. C. PALMER, und N. P. RESTIFO (2005b):

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Trends Immunol. 26: 111-117.

KLEIN, E., G. KLEIN, J. S. NADKARNI, J. J. NADKARNI, H. WIGZELL, und P. CLIFFORD (1967):

Surgace IgM specificity on cells derived from a Burkitt's lymphoma.

Lancet 2: 1068-1070.

KLEIN, W. R., G. E. BRAS, W. MISDORP, P. A. STEERENBERG, W. H. DE JONG, R. H.

TIESJEMA, A. W. KERSJES, und E. J. RUITENBERG (1986):

Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomi-sed clinical trial.

Cancer Immunol. Immunother. 21: 133-140.

KORANGY, F., L. A. ORMANDY, J. S. BLECK, J. KLEMPNAUER, L. WILKENS, M. P.

MANNS, und T. F. GRETEN (2004):

Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in he-patocellular carcinoma.

Clin. Cancer Res. 10: 4332-4341.

KUBALL, J., F. W. SCHMITZ, R. H. VOSS, E. A. FERREIRA, R. ENGEL, P. GUILLAUME, S. STRAND, P. ROMERO, C. HUBER, L. A. SHERMAN, und M. THEOBALD (2005):

Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.

Immunity. 22: 117-129.

KUSMARTSEV, S., und D. I. GABRILOVICH (2006):

Role of immature myeloid cells in mechanisms of immune evasion in cancer.

Cancer Immunol. Immunother. 55: 237-245.

LALVANI, A., R. BROOKES, S. HAMBLETON, W. J. BRITTON, A. V. HILL, und A. J.

MCMICHAEL (1997):

Rapid effector function in CD8+ memory T cells.

J. Exp. Med. 186: 859-865.

LANKAT-BUTTGEREIT, B., und R. TAMPE (2002):

The transporter associated with antigen processing: function and implications in human diseases.

Physiol Rev. 82: 187-204.

LANZAVECCHIA, A., und F. SALLUSTO (2001):

Antigen decoding by T lymphocytes: from synapses to fate determination.

Nat. Immunol. 2: 487-492.

LATOUCHE, J. B., und M. SADELAIN (2000):

Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.

Nat. Biotechnol. 18: 405-409.

LEVINE, B. L., J. COTTE, C. C. SMALL, R. G. CARROLL, J. L. RILEY, W. B. BERN-STEIN, D. E. VAN EPPS, R. A. HARDWICK, und C. H. JUNE (1998):

Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costi-mulation.

J. Hematother. 7: 437-448.

LIU, Y. J., H. KANZLER, V. SOUMELIS, und M. GILLIET (2001):

Dendritic cell lineage, plasticity and cross-regulation.

Nat. Immunol. 2: 585-589.

LOWSETH, L. A., N. A. GILLETT, I. Y. CHANG, B. A. MUGGENBURG, und B. B. BO-ECKER (1991):

Detection of serum alpha-fetoprotein in dogs with hepatic tumors.

J. Am. Vet. Med. Assoc. 199: 735-741.

LOZZIO, C. B., und B. B. LOZZIO (1975):

Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Blood 45: 321-334.

LYNCH, D. H., und R. E. MILLER (1994):

Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.

J. Exp. Med. 179: 31-42.

LYONS, A. B., und C. R. PARISH (1994):

Determination of lymphocyte division by flow cytometry.

J. Immunol. Methods 171: 131-137.

MACARY, P. A., C. T. TOO, und X. DAI (2006):

Targeting tumours by adoptive transfer of immune cells.

Clin. Exp. Pharmacol. Physiol 33: 569-574.

MACKENSEN, A., G. CARCELAIN, S. VIEL, M. C. RAYNAL, H. MICHALAKI, F. TRIEBEL, J. BOSQ, und T. HERCEND (1994):

Direct evidence to support the immunosurveillance concept in a human regressive mela-noma.

J. Clin. Invest 93: 1397-1402.

MACKENSEN, A., B. HERBST, J. L. CHEN, G. KOHLER, C. NOPPEN, W. HERR, G. C.

SPAGNOLI, V. CERUNDOLO, und A. LINDEMANN (2000):

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells gene-rated in vitro from CD34(+) hematopoietic progenitor cells.

Int. J. Cancer 86: 385-392.

MADDEN, D. R. (1995):

The three-dimensional structure of peptide-MHC complexes.

Annu. Rev. Immunol. 13: 587-622.

MALKOVSKA, V., F. K. CIGEL, N. ARMSTRONG, B. E. STORER, und R. HONG (1992):

Antilymphoma activity of human gamma delta T-cells in mice with severe combined immu-ne deficiency.

Cancer Res. 52: 5610-5616.

MANNERING, S. I., J. L. MCKENZIE, und D. N. HART (1998):

Optimisation of the conditions for generating human DC initiated antigen specific T lym-phocyte lines in vitro.

J. Immunol. Methods 219: 69-83.

MARTIN DE LAS, M. J., J. C. GOMEZ-VILLAMANDOS, J. PEREZ, E. MOZOS, M.

ESTRADO, und A. MENDEZ (1995):

Immunohistochemical evaluation of canine primary liver carcinomas: distribution of alpha-fetoprotein, carcinoembryonic antigen, keratins and vimentin.

Res. Vet. Sci. 59: 124-127.

MAUS, M. V., A. K. THOMAS, D. G. LEONARD, D. ALLMAN, K. ADDYA, K. SCHLIEN-GER, J. L. RILEY, und C. H. JUNE (2002):

Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

Nat. Biotechnol. 20: 143-148.

MCMICHAEL, A. J., F. M. GOTCH, G. R. NOBLE, und P. A. BEARE (1983):

Cytotoxic T-cell immunity to influenza.

N. Engl. J. Med. 309: 13-17.

MEDZHITOV, R., und C. A. JANEWAY, Jr. (1997):

Innate immunity: the virtues of a nonclonal system of recognition.

Cell 91: 295-298.

MEIDENBAUER, N., J. MARIENHAGEN, M. LAUMER, S. VOGL, J. HEYMANN, R.

ANDREESEN, und A. MACKENSEN (2003):

Survival and tumor localization of adoptively transferred Melan-A-specific T cells in mela-noma patients.

J. Immunol. 170: 2161-2169.

MITCHELL, M. S. (2002):

Cancer vaccines, a critical review--Part I.

Curr. Opin. Investig. Drugs 3: 140-149.

MITCHELL, M. S., D. DARRAH, D. YEUNG, S. HALPERN, A. WALLACE, J. VOLAND, V.

JONES, und J. KAN-MITCHELL (2002):

Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope.

J. Clin. Oncol. 20: 1075-1086.

MIZEJEWSKI, G. J. (1995):

Alpha-fetoprotein signal sequences: a proposed mechanism for subcellular localization and organelle targeting.

J. Theor. Biol. 176: 103-113.

MOHR, S., G. D. LEIKAUF, G. KEITH, und B. H. RIHN (2002):

Microarrays as cancer keys: an array of possibilities.

J. Clin. Oncol. 20: 3165-3175.

MOROZ, A., C. EPPOLITO, Q. LI, J. TAO, C. H. CLEGG, und P. A. SHRIKANT (2004):

IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity:

comparative evaluation of IL-2, IL-15, and IL-21.

comparative evaluation of IL-2, IL-15, and IL-21.